title: Factor I-dependent inactivation of human complement C4b of the classical pathway by C3b/C4b receptor (CR1, CD35) and membrane cofactor protein (MCP, CD46).
abstract: Proteolytic inactivation of C4b is a crucial step for regulation of the classical complement pathway. A plasma protease factor I and membrane cofactors, C3b/C4b receptor (CR1) and membrane cofactor protein (MCP), participate in the regulation of cell-bound C4b although the physiological potency of these cofactors remains unknown. We have examined the optimal conditions of the factor I-mediated C4b regulatory system using purified cofactors. CR1 being a cofactor at a cofactor/C4b ratio less than 0.1 (w/w), fluid phase C4b, and methylamine-treated C4 (C4ma) were degraded by factor I into C4bi: minimal Cd4 was generated in the fluid phase. Liposome-bound C4b (LAC4b), on the other hand, was degraded into C4c and C4d. CR1 showed two optimal pHs (6.0 and 7.5) for fluid phase C4b, but one (6.0) for LAC4b, and in both cases low conductivity conditions enhanced the C4bi generation. CR1 cofactor activity was barely influenced by the NP-40 concentration. On the other hand, MCP degraded C4b and C4ma, as a factor I-cofactor, more efficiently into C4c and C4d. Though MCP cofactor activity, like that of CR1, was enhanced under low conductivity conditions, it has only one optimal pH, 6.0, in both fluid and solid phases. Furthermore, as in the case of C3b cleavage, a sufficient NP-40 concentration to solubilize membrane was needed for MCP to express full cofactor activity for C4b, in contrast to CR1. MCP was less potent for C4b inactivation than for C3b inactivation, while CR1 acted as a slightly more effective cofactor for C4b cleavage than for C3b cleavage.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Immunology, Center for Adult Diseases Osaka.
authors.forename: T
authors.initials: T
authors.lastname: Masaki
authors.forename: M
authors.initials: M
authors.lastname: Matsumoto
authors.forename: I
authors.initials: I
authors.lastname: Nakanishi
authors.forename: R
authors.initials: R
authors.lastname: Yasuda
authors.forename: T
authors.initials: T
authors.lastname: Seya
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D015935:Complement C4b / Q000037:antagonists & inhibitors*; D003171:Complement Pathway, Classical; D003902:Detergents; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007962:Leukocytes / Q000276:immunology; D051916:Membrane Cofactor Protein; D008562:Membrane Glycoproteins / Q000378:metabolism; D017830:Octoxynol; D011092:Polyethylene Glycols; D011951:Receptors, Complement / Q000378:metabolism; D017463:Receptors, Complement 3b
chemical_list: D015703:Antigens, CD; C497857:CD46 protein, human; D003902:Detergents; D051916:Membrane Cofactor Protein; D008562:Membrane Glycoproteins; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D011092:Polyethylene Glycols; D015935:Complement C4b; D005340:Fibrinogen; D017830:Octoxynol; C010615:Nonidet P-40